RespiGam/PREVENT Study Questioned
| Autor: | M. J Bouthillier, E. M. Connor, D. A. Carlin, F. H. Top |
|---|---|
| Rok vydání: | 1997 |
| Předmět: | |
| Zdroj: | PEDIATRICS. 100:275-275 |
| ISSN: | 1098-4275 0031-4005 |
| DOI: | 10.1542/peds.100.2.275 |
| Popis: | To the Editor. The publication of the PREVENT trial allows the first opportunity to critically analyze data used by the Food and Drug Administration over 1 year ago to approve RespiGam for reducing the incidence and duration of respiratory syncytial virus (RSV) hospitalization.1 The PREVENT Study Group concluded that RespiGam prophylaxis decreases hospital use from RSV infections by decreasing the incidence of hospitalization (uncorrected χ2; P = .047) and the total number of hospital days/100 children ( P = .045), but there are alternative ways to assess the presented data. The majority of statisticians would use Yates' continuity correction with χ2 when analyzing hospitalization due to RSV.2 When the χ2 is performed … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|